Anavex Life Sciences Corp (AVXL)

[nidan7500]

In summary, a targeted, personalized, precision medicine approach that addresses the multiple potential contributors to cognitive decline for each patient shows promise for the treatment of Alzheimer’s disease and its harbingers, MCI and SCI. The improvements documented in the 100 patients reported here provide support for the performance of a prospective, randomized, controlled clinical trial, especially given the current lack of effective treatment for this common and otherwise terminal illness.

Makes perfect sense and does not contradict/conflict w/Homeostasis thinking. One size does not fit all. Biomarkers matter. The dark period of Amyloid thesis if finally over.